Pre-eclampsia secondary prevention: Difference between revisions

	Pre-eclampsia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Pre-eclampsia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Pre-eclampsia secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Pre-eclampsia secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Pre-eclampsia secondary prevention
CDC on Pre-eclampsia secondary prevention
Pre-eclampsia secondary prevention in the news
Blogs on Pre-eclampsia secondary prevention
Directions to Hospitals Treating Pre-eclampsia
Risk calculators and risk factors for Pre-eclampsia secondary prevention

Revision as of 17:15, 10 October 2020

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sara Zand, M.D.[2]

Blood pressure monitoring
Repeated assessment of proteinuria if the result is negative
Clinical evaluation about clonus
Measurement of blood test twice weekly for hemoglubin,patelet count, uric acid liver enzyme test, renal function test

@@ Line 3: / Line 3: @@
 {{CMG}} {{AE}} {{Sara.Zand}}
 == Overview ==
+*Secondary prevention strategies following [[preeclampsia]] include the fo;;owing:
+:* [[Blood pressure]] monitoring
+:* Repeated assessment of [[proteinuria]] if the result is negative
+:* Clinical evaluation about [[clonus]]
-Maternal monitoring in preeclampsia should include BP monitoring, repeated assessments for proteinuria if it is not already present, clinical assessment including clonus, and a minimum of twice weekly blood tests for hemoglobin, platelet count, and tests of liver and renal function, including uric acid, the latter being associated with worse maternal and fetal outcomes.
+:* Measurement of [[blood test]] twice weekly for [[hemoglubin]],[[patelet count]], [[uric acid]] [[liver enzyme test]], [[renal function test]]